Cefteram
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 574462

CAS#: 82547-58-8

Description: Cefteram is a cephalosporin antibiotic. Its prodrug is Cefteram Pivoxil, which is used in the treatment of infections caused by bacteria. It works by killing bacteria or preventing their growth. Cefditoren pivoxil is also used to treat some throat and lung infections, including bronchitis and tonsillitis. It is also used to treat some skin infections.

Chemical Structure

img
Cefteram
CAS# 82547-58-8
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 574462
Name: Cefteram
CAS#: 82547-58-8
Chemical Formula: C16H17N9O5S2
Exact Mass: 479.08
Molecular Weight: 479.490
Elemental Analysis: C, 40.08; H, 3.57; N, 26.29; O, 16.68; S, 13.37

Price and Availability

Size Price Availability Quantity
1mg USD 85 Ready to ship
5mg USD 150 Ready to ship
10mg USD 250 Ready to ship
25mg USD 550 Ready to ship
50mg USD 950 Ready to ship
100mg USD 1650 Ready to ship
200mg USD 2950 Ready to ship
Bulk inquiry

Synonym: Antibiotic T 2525; Cefteram; Cefterame; Ceftetrame; Ro 19-5247; Ro-19-5247; Ro19-5247; T2525; T 2525; T2525; Ro 195247; Ro-195247; Ro195247;

IUPAC/Chemical Name: (6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-[(5-methyl-2H-tetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic Acid

InChi Key: XSPUSVIQHBDITA-RKYNPMAHSA-N

InChi Code: InChI=1S/C16H17N9O5S2/c1-6-20-23-24(21-6)3-7-4-31-14-10(13(27)25(14)11(7)15(28)29)19-12(26)9(22-30-2)8-5-32-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b22-9-/t10-,14-/m1/s1

SMILES Code: O=C(C(N12)=C(CN3N=C(C)N=N3)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Cefteram is a cephalosporin antibiotic.
In vitro activity: TBD
In vivo activity: TBD

Preparing Stock Solutions

The following data is based on the product molecular weight 479.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: TBD
In vitro protocol: TBD
In vivo protocol: TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Yue Y, Wang J, Zhao Y, Li S, Han J, Zhang Y, Zhang Q, Han F. Impurity profiling of Cefteram pivoxil based on Fourier transform ion cyclotron resonance MS. J Pharm Biomed Anal. 2020 Nov 30;191:113591. doi: 10.1016/j.jpba.2020.113591. Epub 2020 Aug 29. PMID: 32889346.


2: Oyama S, Hosohata K, Inada A, Niinomi I, Mori Y, Yamaguchi Y, Uchida M, Iwanaga K. Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. Ther Clin Risk Manag. 2018 Sep 5;14:1599-1604. doi: 10.2147/TCRM.S168696. PMID: 30233195; PMCID: PMC6130309.


3: Hosaka S, Okamura Y, Tokunaga Y. Preparation of Fine Particles with Improved Solubility Using a Complex Fluidized-Bed Granulator Equipped with a Particle- Sizing Mechanism. Chem Pharm Bull (Tokyo). 2016;64(6):644-9. doi: 10.1248/cpb.c15-00640. PMID: 27250799.


4: Funatsu T, Mizunaga S, Fukuda Y, Nomura N, Hashido H, Mitsuyama J, Hatano M, Yamaoka K, Watanabe K, Asano Y, Suematsu H, Sawamura H, Matsukawa Y, Ohta H, Yamagishi Y, Mikamo H, Matsubara S, Shibata N; Working Group of Total Anti- biogram Study Group; Research Laboratories; Development Division; Toyama Chemical Co Ltd. [Sensitivity surveillance of Streptococcus pneumoniae isolates for several antibacterial agents in Gifu and Aichi prefectures (2011-2012)]. Jpn J Antibiot. 2015 Aug;68(4):225-42. Japanese. PMID: 26625536.


5: Baba H, Sato Y, Toyonaga Y, Hanaki H, Sunakawa K. Nationwide survey of the development of drug resistance in the pediatric field in 2007, 2010, and 2012: drug sensitivity of Haemophilus influenzae serotype b strain in Japan. J Infect Chemother. 2015 Apr;21(4):277-83. doi: 10.1016/j.jiac.2014.12.006. Epub 2014 Dec 26. PMID: 25618776.


6: Eto M, Mizunaga S, Fukuda Y, Nomura N, Matsukawa Y, Mitsuyama J, Matsubara S, Yamaoka K, Watanabe K, Asano Y, Suematsu H, Sawamura H, Hashido H, Yamagishi Y, Mikamo H. [Sensitivity surveillance of Streptococcus pneumoniae isolates for several antibacterial agents in Gifu and Aichi prefecture (2010-2011)]. Jpn J Antibiot. 2013 Oct;66(5):265-82. Japanese. PMID: 24527517.


7: Takakura M, Fukuda Y, Nomura N, Mitsuyama J, Yamaoka K, Asano Y, Sawamura H, Katsuragawa K, Hashido H, Matsukawa Y, Matsubara S, Oota H, Watanabe K, Yamagishi Y, Mikamo H; Working Group of Tokai Anti-biogram Study Group. [Antibacterial susceptibility surveillance of Haemophilus influenzae isolated from pediatric patients in Gifu and Aichi prefectures (2009-2010)]. Jpn J Antibiot. 2012 Oct;65(5):305-21. Japanese. PMID: 23383433.


8: Furuya Y, Fukuda Y, Nomura N, Mitsuyama J, Yamaoka K, Asano Y, Sawamura H, Suematsu H, Teraji M, Kawahara Y, Matsukawa Y, Matsubara S, Miyabe T, Arai T, Watanabe K, Mikamo H; Research Laboratories; Toyama Chemical Co., Ltd; Working Group of Tokai Anti-biogram Study Group. [Sensitivity surveillance of Streptococcus pneumoniae isolates for several antibacterial agents in Gifu and Aichi prefecture (2008-2009)]. Jpn J Antibiot. 2012 Feb;65(1):1-14. Japanese. PMID: 22808690.


9: Jin HJ, Kim JE, Kim JH, Ye YM, Park HS. New sensitization to house dust mites in cefteram-induced occupational asthma: a case report. Allergy Asthma Immunol Res. 2011 Apr;3(2):132-4. doi: 10.4168/aair.2011.3.2.132. Epub 2011 Feb 14. PMID: 21461254; PMCID: PMC3062793.


10: Okumura A, Morita M, Ikeno M, Abe S, Shimizu T. Acute encephalopathy in a child with secondary carnitine deficiency due to pivalate-conjugated antibiotics. Pediatr Infect Dis J. 2011 Jan;30(1):92. doi: 10.1097/INF.0b013e3181fe3953. PMID: 21173681.


11: Kawamoto H, Nomura N, Mitsuyama J, Yamaoka K, Asano Y, Sawamura H, Suematsu H, Teraji M, Hashido H, Matsukawa Y, Matsubara S, Miyabe T, Mikamo H, Watanabe K. [Sensitivity surveillance of streptococci isolates for several antibiotics in Gifu prefecture (2005-2007)]. Jpn J Antibiot. 2009 Dec;62(6):509-24. Japanese. PMID: 20545086.


12: Wei F, Zhu R, Zhao W, Yang J, Cai Z, Hu Q. Pharmacokinetics and bioequivalence studies of cefteram pivoxil in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2009 Jul-Sep;34(3-4):157-62. doi: 10.1007/BF03191167. PMID: 20166432.


13: Yamagishi Y, Izumi K, Tanaka K, Watanabe K, Mikamo H. [Evaluation of antimicrobial prophylaxis after normal delivery]. Jpn J Antibiot. 2009 Apr;62(2):103-15. Japanese. PMID: 19673352.


14: Sakata H. [T serotypes distribution and antimicrobial susceptibility of Streptococcus pyogenes in children with pharyngotonsillitis in Asahikawa]. Jpn J Antibiot. 2008 Dec;61(6):359-65. Japanese. PMID: 19288853.


15: Working Group of Tokai Anti-biogram Study Group, Kaeriyama M, Mizunaga S, Mitsuyama J, Yamaoka K, Asano Y, Sawamura H, Suematsu H, Teraji M, Tsuchiya M, Hashido H, Matsukawa Y, Matsubara S, Miyabe T, Watanabe K, Mikamo H. [Sensitivity surveillance of Haemophilus influenzae isolates for several antibiotics in Gifu Prefecture (2006)]. Jpn J Antibiot. 2008 Aug;61(4):195-208. Japanese. PMID: 19024643.


16: Zou J, Di B, Wu CY, Hu Q, Li JH, Zhu Y, Fan H, Xiao D, Wang GJ. Pharmacokinetic and bioequivalence comparison of a single 100-mg dose of cefteram pivoxil powder suspension and tablet formulations: a randomized- sequence, open-label, two-period crossover study in healthy Chinese adult male volunteers. Clin Ther. 2008 Apr;30(4):654-60. doi: 10.1016/j.clinthera.2008.04.003. PMID: 18498914.


17: Lee DS, Lee JM, Kim SU, Chang KT, Lee SH. Ceftezole, a cephem antibiotic, is an alpha-glucosidase inhibitor with in vivo anti-diabetic activity. Int J Mol Med. 2007 Sep;20(3):379-83. PMID: 17671744.


18: Fujimura T, Yoshida I, Yamano Y. [Susceptibility of clinical isolates from primary care clinics to oral antibacterial agents]. Jpn J Antibiot. 2007 Feb;60(1):17-30. Japanese. PMID: 17436860.


19: Sakata H. [Relationship between protein binding and antimicrobial activities of antibiotics against Streptococcus pneumoniae and Haemophilus influenzae]. Jpn J Antibiot. 2006 Oct;59(5):373-81. Japanese. PMID: 17180806.


20: Onodera S, Kiyota H, Endo K, Suzuki H, Hosobe T, Takahashi T, Egawa S, Kobayashi I. Enhancement of antimicrobial activities of cefteram or clavulanic acid/amoxicillin against cefixime-resistant Neisseria gonorrhoeae in the presence of clarithromycin or azithromycin. J Infect Chemother. 2006 Aug;12(4):207-9. doi: 10.1007/s10156-006-0447-x. PMID: 16944260.